Trends in overall survival and costs of multiple myeloma, 2000–2014
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Trends in overall survival and costs of multiple myeloma, 2000–2014
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 9, Pages 1915-1921
Publisher
Springer Nature
Online
2016-12-25
DOI
10.1038/leu.2016.380
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia
- (2016) Pei-Jung Lin et al. MEDICAL CARE
- Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
- (2016) Ella Willenbacher et al. PLoS One
- Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States
- (2015) Xue Song et al. CURRENT MEDICAL RESEARCH AND OPINION
- Five Myths About Cancer Care In America
- (2014) Dana P. Goldman et al. HEALTH AFFAIRS
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
- (2014) Lotfi Benboubker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States
- (2013) Joan L. Warren et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data
- (2013) A. Teitelbaum et al. ONCOLOGIST
- The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone Versus Thalidomide Plus Melphalan and Prednisone or Lenalidomide Plus Melphalan and Prednisone With Continuous Lenalidomide Maintenance Treatment
- (2013) L. P. Garrison et al. ONCOLOGIST
- How should we treat newly diagnosed multiple myeloma patients?
- (2013) M.-V. Mateos et al. Hematology-American Society of Hematology Education Program
- Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups
- (2012) Sikander Ailawadhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
- (2010) Maria-Victoria Mateos et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is Value in Health Care?
- (2010) Michael E. Porter NEW ENGLAND JOURNAL OF MEDICINE
- Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
- (2009) Jean-Luc Harousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started